My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Semagacestat (LY-450139; LY-4501)
    Semagacestat (LY-450139; LY-4501)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0716
    CAS #: 425386-60-3Purity ≥98%

    Description: Semagacestat (also known as LY450139; LY4501) is a novel and potent γ-secretase inhibitor/blocker for Aβ42, Aβ40 and Aβ38 with the potential for treating Alzheimer's disease. It inhibits Aβ42, Aβ40 and Aβ38 with IC50 calues of 10.9 nM, 12.1 nM and 12.0 nM, it also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Semagacestat was in Phase III trials, but was terminated in August 2010, due to a  disppointing performance.

    References: J Neurosci. 2012 Feb 8;32(6):2037-50; J Neurochem. 2009 Sep;110(5):1377-87. 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)361.44
    FormulaC19H27N3O4
    CAS No.425386-60-3
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 72 mg/mL (199.2 mM)
    Water: <1 mg/mL
    Ethanol: 41 mg/mL (113.4 mM)
    Solubility (In vivo)0.5% methylcellulose: 30 mg/mL
    SynonymsLY450139; LY-450139; Semagacestat; LY4501; LY-4501; LY 4501; LY 450139 

    Chemical Name: (S)-2-hydroxy-3-methyl-N-((S)-1-(((S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-yl)amino)-1-oxopropan-2-yl)butanamide

    SMILES Code: CC(C)[[email protected]](O)C(N[[email protected]@H](C)C(N[[email protected]@H]1C(N(C)CCC2=CC=CC=C12)=O)=O)=O


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Semagacestat reduces the secretion of Aβ42, Aβ40 and Aβ38 from H4 human glioma cells stably overexpressing human wild-type APP into the culture medium, with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, respectively, without affecting cell viability. Semagacestat also increases β-CTF in cell lysates with ECmax of 16.0 nM, and the increase can be unexpectedly attenuated at high concentrations. Semagacestat inhibits Notch signaling with IC50 of 14.1 nM, and shows minimal Notch-sparing selectivity with Notch IC50/Aβ42 IC50 only 1.3. Semagacestat causes a concentration-dependent decrease in Aβ40 secreted into the medium with IC50 of 111 nM from murine CTX expressing endogenous murine APP, but murine Aβ42 formation in CTX is roughly 12-fold less than Aβ40 in accordance with data for neurons from wild type mice.


    Kinase Assay: H4 human glioma cells stably overexpressing human wild-type APP695 are treated with Semagacestat at various concentrations for 24 hours. Levels of Aβ42, Aβ40, and Aβ38 in the media are measured using separate ELISA kits. The expression vector of the constitutively active form of Notch (NotchΔE), encoding bases 1-60 and 5193-6657 of the human Notch1 coding region (NM_017617), is constructed into a pcDNA3.1 vector with a sequence modification from mouse to human. Notch signaling activity is evaluated using Cignal RBP-Jk Reporter Assay kit. RBP-Jk protein [CSL/CBF1/Su(H)/Lag1] is a transcription factor activated with Notch intracellular domain produced by γ-secretase. H4 cells are transiently transfected with the human NotchΔE expression vector and the RBP-Jk-responsive luciferase construct using Lipofectamine 2000, and then exposed to various concentrations of Semagacestat for 16 hours. Notch signaling is measured based on luciferase activity in the cell lysate using the Dual-Glo Luciferase Assay System.


    Cell Assay: Cells (Murine cortical neurons and cerebellar granule cells) are incubated with Semagacestat for 24 hours. For detection of cell viability, the percentage of viable cells is quantified by their capacity to reduce 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) following incubation with 0.5 mg/mL MTT for 60 minutes. For the detection of sAPP species, cells are lysed and analysed by western blotting.

    In VivoOral administration of Semagacestat (1 mg/kg) to 5.5-month old APP-transgenic Tg2576 mice significantly ameliorates memory deficits on spatial working memory using the Y-maze task, which disappears after 8 days subchronic dosing. LY450139 decreases hippocampal levels of both Aβ42 and Aβ40 at 10 mg/kg (22-23% reduction) and 30 mg/kg (36-41% reduction) and increases β-CTF at 0.3-10 mg/kg in a dose dependent manner with no inhibition on the processing of other γ-secretase substrates, such as Notch, N-cadherin or EphA4, in the brain, but impairs normal cognition in wild-type mice and 3-month-old Tg2576 mice failing to restore cognitive deficits in the Y-maze test.
    Animal model Female Tg2576 mice expressing human APP695 with the Swedish mutation (K670N/M671L)
    Formulation & DosageDissolved in 10.5% methyl cellulose;  30 mg/kg; Oral gavage
    References

    J Neurosci. 2012 Feb 8;32(6):2037-50; J Neurochem. 2009 Sep;110(5):1377-87. 


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Semagacestat (LY450139) Semagacestat (LY450139) 
    Semagacestat (LY450139)
    Drug effects on APP processing and Notch signaling in cells. J Neurosci. 2012 Feb 8;32(6):2037-50. 
    Semagacestat (LY450139)
    Acute and subchronic drug effects on cognitive deficits in Tg2576 mice (Experiment 1). J Neurosci. 2012 Feb 8;32(6):2037-50. 
    Semagacestat (LY450139)
    Subchronic drug effects on cognitive deficits in Tg2576 mice at high doses that robustly reduce hippocampal Aβ levels (Experiment 2). J Neurosci. 2012 Feb 8;32(6):2037-50.  
     
    Semagacestat (LY450139)
    Acute and subchronic drug effects on normal cognitive function in WT mice (Experiment 4). J Neurosci. 2012 Feb 8;32(6):2037-50. 
    Semagacestat (LY450139)
    Localized accumulation of human β-CTF in Tg2576 mouse hippocampus following GSI treatment. J Neurosci. 2012 Feb 8;32(6):2037-50. 
    Semagacestat (LY450139)
    Localized accumulation of APP-CTFs in Tg2576 mouse hippocampus following GSI treatment. J Neurosci. 2012 Feb 8;32(6):2037-50. 
     
    Semagacestat (LY450139)
    Localized accumulation of mouse endogenous APP-CTFs in WT mouse hippocampus following GSI treatment. J Neurosci. 2012 Feb 8;32(6):2037-50. 


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?